Amoxicillin Alone Versus Amoxicillin/Clavulanate for Community-acquired Pneumonia in Patients Aged 65 Years or Older, and Hospitalized in a Non-intensive Care Unit Ward — CAPTAIN

Community-acquired Pneumonia Clinical Trial

Official title:
Amoxicillin Alone Versus Amoxicillin/Clavulanate for Community-acquired Pneumonia in Patients Aged 65 Years or Older, and Hospitalized in a Non-intensive Care Unit Ward: a Non-inferiority Randomized Controlled Trial

Status Not yet recruiting

Clinical Trial Summary

Reduce inappropriate antibiotic use is a priority of public health agencies. Community-acquired pneumonia (CAP) is one of the most important indications for antibiotic prescriptions. In the majority of the studies of CAP, there is a large proportion of cases with no pathogen identified. Thus, the choice of the empirical antibiotic depends on the most likely pathogen, individual risk factors, comorbidities, and allergies. Patients aged 65 years or older are often treated with amoxicillin/clavulanate or with another broad-spectrum antibiotic (third-generation cephalosporins, antipneumococcal fluoroquinolone). However, broad-spectrum antibiotic prescription in CAP is debated and concerns exist about side-effects and selective pressure for resistance. Due to lack of head-to-head antibiotic comparisons, a recent Cochrane review concluded that current evidence from Randomized Clinical Trials (RCTs) is insufficient to make evidence-based recommendations for the choice for antibiotic to be used, highlighting an important evidence gap.

Clinical Trial Description

Thus, the goal of the proposed trial is to compare clinical efficacy and safety of two CAP antimicrobial treatments, amoxicillin and amoxicillin/clavulanate, in patients aged 65 years or older and hospitalized in a non-intensive care unit (ICU) ward. The CAPTAIN study will be a multi-center, randomized, open, non-inferiority trial comparing clinical efficacy at Day 30 among patients ≥65 years of age, and hospitalized in a non-ICU ward, treated with narrow-spectrum (amoxicillin) versus broad-spectrum (amoxicillin/clavulanate) antimicrobial therapy for CAP. This will be a pivotal clinical trial that will provide evidence to inform CAP treatment guidelines. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06229288
Study type	Interventional
Source	Nantes University Hospital
Contact	Emmanuel MONTASSIER, Professor
Phone	02 53 48 20 38
Email	emmanuel.montassier@chu-nantes.fr
Status	Not yet recruiting
Phase	Phase 3
Start date	March 15, 2024
Completion date	April 15, 2027

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05722938` - Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)	Phase 3
Terminated	`NCT04972318` - Two Different Ventilatory Strategies in Acute Respiratory Distress Syndrome Due to Community-acquired Pneumonia	N/A
Recruiting	`NCT06065618` - Characteristics of Hospitalized Patients With Community-acquired Pneumonia
Not yet recruiting	`NCT03675178` - Clinical Study of Anerning Particle for the Treatment of Childhood Community-acquired Pneumonia	Phase 4
Not yet recruiting	`NCT04166110` - Antibiotic Therapy In Respiratory Tract Infections	N/A
Completed	`NCT02380352` - Short-course Antimicrobial Therapy for Paediatric Respiratory Infections	Phase 4
Completed	`NCT01671280` - Drug Use Investigation Of Azithromycin IV For Community-Acquired Pneumonia Or Pelvic Inflammatory Disease (Regulatory Post Marketing Commitment Plan)	N/A
Completed	`NCT02555852` - Proton Pump Inhibitors and Risk of Community-acquired Pneumonia	N/A
Recruiting	`NCT00752947` - Efficacy and Safety Trial to Assess Moxifloxacin in Treating Community-Acquired Pneumonia (CAP) With Aspiration Factors	Phase 4
Completed	`NCT00140023` - Azithromycin Microspheres in Patients With Low Risk Community Acquired Pneumonia	Phase 3
Recruiting	`NCT04089787` - Shortened Antibiotic Treatment of 5 Days in Community-Acquired Pneumonia	Phase 4
Completed	`NCT05356494` - Postural Drainage and PEP Technique in Community Acquired Pneumonia	N/A
Completed	`NCT05133752` - Oral Nemonoxacin in Treating Elderly Patients With CAP	Phase 4
Not yet recruiting	`NCT06291012` - Stopping Pneumonia Antibiotherapy Regimen Early	Phase 4
Recruiting	`NCT05002192` - A Retrospective, Real-world Study of ELP Used in the Expectorant Treatment of Community-acquired Pneumonia
Completed	`NCT03452826` - Combined Use of a Respiratory Broad Panel mPCR and Procalcitonin to Reduce Duration of Antibiotics Exposure in Patients With Severe Community-Acquired Pneumonia	N/A
Terminated	`NCT04071041` - Effect of Albumin Administration in Hypoalbuminemic Hospitalized Patients With Community-acquired Pneumonia.	Phase 3
Completed	`NCT03474991` - KIDS-STEP_Betamethasone Therapy in Hospitalised Children With CAP	Phase 3
Withdrawn	`NCT01662258` - Microbiology Testing With the Aim Of Directed Antimicrobial Therapy For CAP	N/A
Completed	`NCT01683487` - Delayed Antibiotic Treatment in Community-acquired Pneumococcal Pneumonia.	Phase 4

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.